Kiyomi Morita

Bunkyo-ku, 1138655, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies.

Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies.

Journal: Nature communications
Published: November 03, 2023

Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.

Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2023

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

Journal: Haematologica
Published: October 18, 2022

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.

Journal: Nature communications
Published: May 11, 2021

Statistical tests for intra-tumour clonal co-occurrence and exclusivity.

Statistical tests for intra-tumour clonal co-occurrence and exclusivity.

Journal: PLoS computational biology
Published: April 28, 2021

B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.

B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.

Journal: British journal of haematology
Published: April 13, 2021

Current status and novel strategy of CML.

Current status and novel strategy of CML.

Journal: International journal of hematology
Published: March 02, 2021

Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.

Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.

Journal: American journal of hematology
Published: February 20, 2021

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.

Journal: Blood advances
Published: February 03, 2021

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.

Journal: Cancer
Published: December 28, 2020

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.

Journal: Blood
Published: December 22, 2020

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Journal: Cancer
Published: December 18, 2020
Showing 1-12 of 24

Last Updated: 09/26/2026